文献速递中医内科中药与中成药合理使用

开心散治疗阿尔茨海默病动物模型的疗效与可能机制:临床前研究的系统评价与Meta分析

Efficacy and possible mechanism of Kai-xin-san in animal models of Alzheimer's disease: a systematic review and meta-analysis of preclinical studies.
PubMed 文献 · Front Pharmacol · 2026-04-23

Meta分析显示开心散可改善Morris水迷宫、新物体识别和Y迷宫表现,并调节Aβ、tau、炎症、氧化应激和胆碱能功能等多重机制。但纳入研究偏倚风险高,提示真实效应可能小于报告值,需高质量临床前研究验证。

要点

  • 开心散可改善AD动物模型的认知行为表现。
  • 开心散可能通过调节Aβ、tau、炎症、氧化应激和胆碱能功能发挥作用。
  • 纳入研究偏倚风险高,真实效应可能小于报告值。

核心结论

  • 开心散可能减轻AD动物模型的认知缺陷,其机制涉及Aβ和tau病理、炎症、氧化应激及胆碱能功能调节。
  • 因偏倚风险高,开心散的真实效应可能小于报告值,需高质量临床前研究后再考虑临床疗效。

研究设计与样本

  • 纳入44项动物研究,共2681只动物。
  • 采用SYRCLE偏倚风险工具评估,STATA 15.0和RevMan 5.4进行Meta分析。
  • 使用亚组分析、Meta回归、敏感性分析、Egger检验和漏斗图,并用改良GRADE方法评估证据质量。

主要发现

  • Morris水迷宫:开心散显著缩短逃避潜伏期,提高目标象限进入频率和在目标象限停留时间。
  • 新物体识别:开心散显著提高相对识别指数;Y迷宫:开心散改善自发交替表现。
  • 开心散降低海马Aβ、tau和AchE,降低血清和海马TNF-α、IL-1β、IL-6和MDA,提高海马ACh和血清及海马SOD。

关键数值与推荐

  • 纳入44项研究,共2681只动物,评估3项行为测试(Morris水迷宫、新物体识别、Y迷宫)和9项生物标志物(Aβ、tau、TNF-α、IL-1β、IL-6、MDA、SOD、AchE、ACh)。
  • 开心散显著改善Morris水迷宫逃避潜伏期、目标象限进入频率和停留时间,以及新物体识别相对识别指数和Y迷宫自发交替表现。
  • 开心散降低海马Aβ、tau和AchE,降低血清和海马TNF-α、IL-1β、IL-6和MDA,提高海马ACh和血清及海马SOD。

临床怎么用

  • 开心散可能作为AD认知障碍的潜在治疗选择,但当前证据来自动物模型,临床转化需谨慎。
  • 临床应用前应等待高质量临床前研究和临床试验验证其疗效与安全性。

局限性

  • 纳入研究偏倚风险高,可能夸大开心散的真实效应。
  • 证据仅来自动物模型,不能直接外推至临床患者。
  • 需要高质量临床前研究以确认疗效后再考虑临床疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Alzheimer's disease (AD) is the most common neurodegenerative disorder, which is associated with impaired cognition. Kai-xin-san (KXS), a classic Chinese herbal formula, has been widely used to treat cognitive disorders. OBJECTIVES: This study aimed to investigate the therapeutic potential and underlying mechanisms of KXS for AD. METHODS: A systematic search of 7 databases was conducted from inception to October 2025, with language restrictions in both Chinese and English. Behavior and biomarkers were assessed as measures of efficacy and mechanism. The risk of bias was assessed by the SYRCLE's risk of bias tool. The meta-analysis was performed by STATA version 15.0 software packages and RevMan 5.4 software. Subgroup, meta-regression, and sensitivity analyses were used to ascertain the robustness of primary analyses, Egger's test and funnel plots were used to assess potential publication bias, and the evidence of evidence was assessed by the modified GRADE approach. RESULTS: This study included 44 studies, involving a total of 2,681 animals, 3 behavioral tests, such as Morris water maze (MWM), novel object recognition (NOR), Y maze, and 9 biomarkers, such as β-amyloid peptide (Aβ), tau protein, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), malondialdehyde (MDA), superoxide dismutase (SOD), acetylcholinesterase (AchE), and acetylcholine (ACh). KXS could significantly shorten escape latency from the target quadrant, and elevate entry frequency into the target quadrant and time spent in the target quadrant in MWM; meanwhile, KXS could also significantly enhance the relative recognition index in NOR, and improve spontaneous alternation performance in Y-maze. Moreover, KXS could decrease Aβ, tau and AchE in the hippocampus, and TNF-α, IL-1β, IL-6, and MDA in both serum and hippocampus, while increase ACh in the hippocampus and SOD in both serum and hippocampus. CONCLUSION: These findings suggest that KXS may alleviates cognitive deficits in AD animal models, which may be attributed to its modulation of multiple mechanisms, including Aβ and tau pathology, inflammation, oxidative stress, and cholinergic function. However, due to the high risk of bias, indicating that the true effects of KXS may be smaller than those reported. Therefore, high-quality preclinical studies are essential before clinical efficacy can be considered.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Wang Q, Xie H, et al. Efficacy and possible mechanism of Kai-xin-san in animal models of Alzheimer's disease: a systematic review and meta-analysis of preclinical studies. Front Pharmacol. 2026. PMID: 42110549. doi:10.3389/fphar.2026.1806181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。